

Stellingen behorende bij het proefschrift

Peptide Receptor Radionuclide Therapy & Oncology

1. Monitoring renal function during follow-up after PRRT with ^{177}Lu -octreotate is redundant, whereas renal function assessment before start of PRRT is obligatory. (this thesis)
2. Imaging with [^{68}Ga]SB3 can improve staging and monitoring of prostate and breast cancer in patients. (this thesis)
3. Dosimetry plays an un-determined role in PRRT with ^{177}Lu -octreotate. (this thesis)
4. Radiation dose thresholds in external beam radiotherapy are not applicable for PRRT with ^{177}Lu -octreotate. (this thesis)
5. Hematological malignancies, induced by PRRT with ^{177}Lu -octreotate, occur in a stochastic manner. (this thesis)
6. Hematological malignancies mainly occur in patients who received PRRT with ^{177}Lu -octreotate and who were pre-treated with a high dose of alkylating chemotherapy. (P. Ruzniewski et al., Endocrine-Related Cancer 2016)
7. The status of PRRT with a combination of radionuclides seems to mimic the situation of advised bed rest in patients with mild traumatic brain injury. (D.J. Kwekkeboom, Nature Reviews Endocrinology 2012)
8. Humans populating high altitude environments have a lower risk of developing cancer. (M. Thiersch, Experimental Cell Research 2017)
9. We cannot know all the facts since they are infinite in number. Therefore, creativity in scientific research is essential to select the most relevant facts. (Jules Henri Poincaré, mathematician)
10. Doing this research is like finding the beginning of a roll of Scotch tape. (Robbert Dijkgraaf, physicist)
11. It's not the destination; it's the (motorcycle) ride.

Hendrik Bergsma
Rotterdam, 26 September 2017